Free antiretroviral therapy key to success of AIDS treatment in developing countries

HIV-infected patients starting highly active antiretroviral therapy (HAART) in developing countries have increased mortality rates in the first months on therapy compared with those in developed countries, according to a paper in this week's issue of The Lancet. The authors state that early diagnosis and assessment of treatment eligibility, coupled with free provision of HAART, might reduce this excess mortality.

HAART has substantially improved the prognosis of HIV-infected patients who have access to these drugs. HAART is being scaled up in developing countries but several factors could limit the effectiveness of the therapy in resource-poor settings.

In this study the researchers compared the ART-LINC Collaboration--a network of 18 HAART programmes in Africa, Asia, and South America--with a similar network of 12 HAART programmes in Europe and North America. They found that mortality was higher in low-income settings than in high-income settings. Patients in low-income countries had lower CD4 cell counts (indicating an increased risk of infection) and more advanced clinical disease when they started treatment. However, the authors state that this only partly explains the higher mortality. They believe accompanying illnesses (comorbidities) such as tuberculosis that are present in many low-income settings may have increased mortality. They also found that the provision of treatment free of charge in low-income settings was strongly associated with lower mortality.

Author Dr Matthias Egger (University of Berne, Switzerland) concludes: "Antiretroviral therapy is feasible and effective in low income settings, but, compared with industrialized countries, mortality is high in the first months. Eligibility for antiretroviral treatment and the need for treatment of tuberculosis should be determined earlier, and HAART should be started before serious comorbidities develop."

In an accompanying Editorial, The Lancet comments: "The start of th

Contact: Joe Santangelo

Page: 1 2

Related medicine news :

1. Study shows interruption of antiretroviral therapy increases risk of disease and death
2. No advantage for four-drug antiretroviral regimen vs. three-drug for initial treatment of HIV-1
3. Sub-Saharan Africans with HIV may achieve favorable levels of antiretroviral therapy adherence
4. Saving antiretroviral treatment in long-term HIV-positive patients
5. Access to antiretrovirals unlikely to reduce HIV infection rates
6. Study sets new gold standard for initial antiretroviral treatment of HIV infection
7. International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy
8. HIV mortality in India drops with introduction of generic antiretroviral therapy
9. Highly active antiretrovirals for HIV can substantially reduce rates of AIDS
10. Chemotherapy with bevacizumab increases risk of blood clots in arteries
11. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone

Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... ... continuing medical education (CME), today announced that the first annual School of Gastrointestinal ... , “The prevention, detection and treatment of gastrointestinal cancers are undergoing transformational change, ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS ... 2015 Golden Bridge Business Awards under the New Products and Services category for ... based sample management software that helps labs organize data and track ...
(Date:12/1/2015)... CHICAGO (PRWEB) , ... December 01, 2015 , ... ... risk quantification and optimization of adjunctive imaging is the focus of numerous abstracts ... (RSNA) meeting, November 29-December 4, 2015. Nine abstracts highlight the use of ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical ... that it has reached its enrollment target of 400 ... trial of aldoxorubicin in patients with previously treated soft ... in Q1 2016. The Phase 3 trial is a randomized, ... from the FDA at 79 sites in ...
(Date:12/1/2015)... Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), a ... of therapies for cardiovascular conditions via the inhalation route, ... in Australia . InCarda is planning ... Australia in the first half of ... medical centers in Adelaide and ...
(Date:12/1/2015)... , Dec. 1, 2015  Booth #3506 – Claymount is ... the annual meeting of the Radiological Society of ... this year. Based in the Netherlands ... Varian Medical Systems (NYSE: VAR ) and is one ... chambers and solid state automatic exposure control systems for controlling ...
Breaking Medicine Technology:
Cached News: